Inspirna is a biopharmaceutical company. Proceeds from the financing will go toward the development of the company’s small molecule inhibitor drugs RGX-202, designed to treat colorectal cancer, and RGX-104, designed to treat lung and endometrial cancer, according to a July 11 press release.
Michael Ginder of Sands Capital and Jack Nielsen of Vivo Capital are set to join Inspirna’s board of directors.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
